৳ 400/unit
Pack: ৳ 11,200
৳ 400/unit
Pack: ৳ 11,200
At a glance
Daclatasvir is an antiviral medication used in combination with Sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection in adults.
Indications
- Chronic hepatitis C virus (HCV) infection (genotypes 1 and 3)
Pharmacology
Daclatasvir is a direct acting antiviral agent (DAA) against the Hepatitis C Virus (HCV). Daclatasvir is an inhibitor of NS5A, a nonstructural protein encoded by HCV. Daclatasvir binds to the N-terminus of NS5A and inhibits both viral RNA replication and virion assembly. Characterization of Daclatasvir-resistant viruses, biochemical studies, and computer modeling data indicate that Daclatasvir interacts with the N-terminus within Domain 1 of the protein, which may cause structural distortions that interfere with NS5A functions.
Dosage
Adult - HCV Genotype 1 (with Sofosbuvir): 60 mg (plus Sofosbuvir 400 mg) orally once daily for 12 weeks.
Adult - HCV Genotype 3 (with Sofosbuvir): 60 mg (plus Sofosbuvir 400 mg) orally once daily for 12 weeks.
Cirrhosis (Child-Pugh B or C) or posttransplant: 60 mg (plus Sofosbuvir 400 mg) + Ribavirin once daily for 12 weeks.
With strong CYP3A4 inhibitors: Reduce dose to 30 mg once daily.
With moderate CYP3A4 inducers: Increase dose to 90 mg once daily.
Side effects
Common Side Effects:
- Fatigue
- Headache
- Nausea
- Insomnia
- Anemia
- Dizziness
- Blurred vision
Serious Side Effects:
- Symptomatic bradycardia when coadministered with Sofosbuvir and Amiodarone
Use in pregnancy
No data with Daclatasvir in pregnant women are available. Animal studies have shown harmful effects. Your doctor will weigh the benefits and any potential risks. Please consult your doctor.
Pregnancy Category: N/A — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Daclatasvir may have significant drug interactions with other drugs, which may lead to loss of therapeutic effect or development of resistance.
- Risk of symptomatic bradycardia when coadministered with Sofosbuvir and Amiodarone.
- May affect your ability to drive (fatigue, dizziness, blurred vision).
- Monitor liver function and HCV viral load regularly during treatment.
- Do not stop taking Daclatasvir without your doctor's advice.
Overdose effects
There is no known antidote for overdose of Daclatasvir. Treatment should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Dialysis is unlikely to significantly reduce plasma concentrations (>99% protein bound).
Storage conditions
Store at room temperature below 30°C, protect from light. Keep out of reach of children.